title: Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation.
abstract: Despite strict pre- and post-transplantation screening, the incidence of new-onset diabetes after transplantation (NODAT) remains as high as 60%. This complication affects the risk of cardiovascular events and patient and graft survival rates. Thus, reducing the impact of NODAT could improve overall transplant success. The pathogenesis of NODAT is multifactorial, and both modifiable and nonmodifiable risk factors have been implicated. Monitoring and controlling the blood glucose profile, implementing multidisciplinary care, performing lifestyle modifications, using a modified immunosuppressive regimen, administering anti-metabolite agents, and taking a conventional antidiabetic approach may diminish the incidence of NODAT. In addition to these preventive strategies, inhibition of dipeptidyl peptidase-4 (DPP4) by the gliptin family of drugs has recently gained considerable interest as therapy for type 2 diabetes mellitus and NODAT. This review focuses on the role of DPP4 inhibitors and discusses recent literature regarding management of NODAT.
authors.affiliation: Transplant Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea ; Convergent Research Consortium for Immunologic Disease, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Sun Woo
authors.initials: SW
authors.lastname: Lim
authors.affiliation: Division of Nephrology, Department of Internal Medicine, Yanbian University Hospital, Yanji, China.
authors.forename: Ji Zhe
authors.initials: JZ
authors.lastname: Jin
authors.affiliation: Transplant Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.|Convergent Research Consortium for Immunologic Disease, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Long
authors.initials: L
authors.lastname: Jin
authors.affiliation: Transplant Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.|Convergent Research Consortium for Immunologic Disease, College of Medicine, The Catholic University of Korea, Seoul, Korea.|Division of Nephrology, Department of Internal Medicine, Yanbian University Hospital, Yanji, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Jin
authors.affiliation: Division of Nephrology, Department of Internal Medicine, Yanbian University Hospital, Yanji, China.
authors.forename: Can
authors.initials: C
authors.lastname: Li
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D006801:Humans; D016377:Organ Transplantation / Q000009:adverse effects*; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4
keywords: Dipeptidyl-peptidase IV inhibitors; Kidney transplantation; New-onset diabetes after transplantation